ACAD vs INTR

For growth investors, Inter & Co, Inc.

(INTR) is the stronger pick with 27. 1% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 4x trailing P/E (48. 5x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 4x versus Inter & Co, Inc. at 18. 7x. On forward P/E, Inter & Co, Inc. is actually cheaper at 1. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Inter & Co, Inc.

(INTR) delivered a total return of +131. 7%, compared to +2. 5% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: INTR returned +131. 7% versus ACAD's -22. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 26β versus Inter & Co, Inc. 's 1. 39β — meaning INTR is approximately 11% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 131% for Inter & Co, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Inter & Co, Inc.

(INTR) is pulling ahead at 27. 1% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Inter & Co, Inc. grew EPS 176. 0% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus 9. 3% for Inter & Co, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INTR leads at 12. 4% versus 9. 8% for ACAD. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Inter & Co, Inc.

(INTR) trades at 1. 9x forward P/E versus 48. 5x for ACADIA Pharmaceuticals Inc. — 46. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACAD: 61. 9% to $34. 78.

In this comparison, INTR (0.

4% yield) pays a dividend. ACAD does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (ACAD: -22. 3%, INTR: +131. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACAD (Healthcare) and INTR (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACAD is a small-cap deep-value stock; INTR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.